• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
July 28, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
June 02, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
May 18, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
May 04, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
March 01, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
February 23, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
January 14, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
January 03, 2022
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
November 11, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
November 08, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 02, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
October 26, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer
October 06, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
September 09, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
August 24, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 04, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team
August 03, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021
July 28, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis
June 25, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Death
Tickers PIRS
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
June 24, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
May 25, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
May 20, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Tickers PIRS
Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021
May 10, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers PIRS
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
April 26, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers PIRS
Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
April 10, 2021
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers PIRS
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap